“…The authors of twenty-two studies from 84 have declared their support for the carrying out of antibody screening for hepatitis C [ 10 , 34 , 39 , 48 , 55 , 58 , 62 , 73 , 77 , 81 , 89 , 117 ], especially in the following situations: erosive LP [ 38 , 60 , 102 , 105 ] patients with different types of LP [ 29 ], risk factors for hepatitis infection [ 33 ], areas of high HCV prevalence [ 8 ], high-level liver enzymes [ 52 , 65 ] or to at least make the patient aware of the possible association between LP and HCV [ 96 ], while others do not [ 75 , 85 , 97 , 98 , 103 , 106 , 113 , 119 ]. Another opinion was that in patients with risk factors for chronic liver diseases or in patients with risk factors for hepatitis C, the chart should be taken with care [ 35 ].…”